The validity and sensitivity of PANSS-6 in treatment-resistant schizophrenia

Acta Psychiatrica Scandinavica
S D ØstergaardChristoph U Correll

Abstract

To test the validity and sensitivity of the six-item version (PANSS-6) of the 30-item Positive and Negative Syndrome Scale (PANSS-30) in treatment-resistant schizophrenia (TRS). Using data from the clozapine phase (2E) of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study, we investigated the following: (i) The scalability of PANSS-6 and PANSS-30; (ii) The correlation between PANSS-6 and PANSS-30 total scores; (iii) Whether PANSS-6 could identify cross-sectional symptom remission; and (iv) The efficacy of clozapine, olanzapine, risperidone and quetiapine in TRS using the 'speed of change' on PANSS-6 and PANSS-30 (change in total score per week) as outcome measures. We found that (i) only PANSS-6 and not PANSS-30 was scalable; (ii) The correlation between PANSS-6 and PANSS-30 total scores was high (Spearman coefficient: 0.85), (iii) PANSS-6 accurately identified cross-sectional symptom remission as defined by the Andreasen et al. criteria; and (iv) The only antipsychotic that caused improvement (speed of change significantly lower than 0 during the first three months of treatment) was clozapine, both when using PANSS-6 (speed of change: -0.50 points/week; 95%CI: -0.84, -0.17) and PANSS-30 (speed of cha...Continue Reading

References

Mar 1, 1975·Acta Psychiatrica Scandinavica·P BechT G Bolwig
May 1, 1989·The British Journal of Psychiatry : the Journal of Mental Science·T R Barnes
Jan 1, 1987·Schizophrenia Bulletin·S R KayL A Opler
Mar 1, 1981·Acta Psychiatrica Scandinavica·P BechA Nagy
Sep 1, 1997·The American Journal of Psychiatry·R R ConleyC A Tamminga
Jan 7, 2003·Archives of General Psychiatry·Herbert Y MeltzerUNKNOWN International Suicide Prevention Trial Study Group
Feb 1, 1960·Journal of Neurology, Neurosurgery, and Psychiatry·M HAMILTON
Nov 19, 2003·Journal of Clinical Psychopharmacology·Robert R ConleyWilliam T Carpenter
Dec 1, 2004·The American Journal of Psychiatry·R Michael BagbyMargarita B Marshall
Mar 3, 2005·The American Journal of Psychiatry·Nancy C AndreasenDaniel R Weinberger
Sep 21, 2005·The New England Journal of Medicine·Jeffrey A LiebermanUNKNOWN Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators
Dec 20, 2011·Clinical Therapeutics·Christoph U CorrellJohn M Kane
Jun 27, 2013·Acta Psychiatrica Scandinavica·S D ØstergaardUNKNOWN STOP-PD Study Group
Jan 9, 2015·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Gagan FervahaGary Remington
Jan 18, 2015·Schizophrenia Research·Jo Ellen WilsonStephan Heckers
Nov 13, 2015·Acta Psychiatrica Scandinavica·S D ØstergaardP Bech
Dec 15, 2015·BMJ : British Medical Journal·Robert D Sheridan
Jul 29, 2017·The American Journal of Psychiatry·Theresa WimberleyHenrik Støvring
Mar 6, 2018·Schizophrenia Bulletin·William T Carpenter

❮ Previous
Next ❯

Citations

Sep 20, 2019·Acta Psychiatrica Scandinavica·J Torous
Sep 19, 2020·Patient Preference and Adherence·Brennan Carrithers, Rif S El-Mallakh
Feb 13, 2021·Schizophrenia Research·Pernille KølbækSøren D Østergaard
Feb 26, 2021·Nordic Journal of Psychiatry·Pernille KølbækSøren D Østergaard

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here